DE60116080D1 - 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol - Google Patents

4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol

Info

Publication number
DE60116080D1
DE60116080D1 DE60116080T DE60116080T DE60116080D1 DE 60116080 D1 DE60116080 D1 DE 60116080D1 DE 60116080 T DE60116080 T DE 60116080T DE 60116080 T DE60116080 T DE 60116080T DE 60116080 D1 DE60116080 D1 DE 60116080D1
Authority
DE
Germany
Prior art keywords
piperidine
phenoxy
diol
benzyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60116080T
Other languages
English (en)
Other versions
DE60116080T2 (de
Inventor
Alexander Alanine
Bernd Buettelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60116080D1 publication Critical patent/DE60116080D1/de
Application granted granted Critical
Publication of DE60116080T2 publication Critical patent/DE60116080T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE60116080T 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol Expired - Lifetime DE60116080T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25
EP00108769 2000-04-25
PCT/EP2001/004305 WO2001081309A2 (en) 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol

Publications (2)

Publication Number Publication Date
DE60116080D1 true DE60116080D1 (de) 2006-01-26
DE60116080T2 DE60116080T2 (de) 2006-08-24

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116080T Expired - Lifetime DE60116080T2 (de) 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol

Country Status (18)

Country Link
US (1) US6432985B2 (de)
EP (1) EP1278730B1 (de)
JP (1) JP3831255B2 (de)
KR (1) KR100527527B1 (de)
CN (1) CN1178914C (de)
AR (1) AR028357A1 (de)
AT (1) ATE313527T1 (de)
AU (1) AU785153B2 (de)
BR (1) BR0110233A (de)
CA (1) CA2407345C (de)
DE (1) DE60116080T2 (de)
DK (1) DK1278730T3 (de)
ES (1) ES2254422T3 (de)
MX (1) MXPA02010573A (de)
PE (1) PE20011229A1 (de)
UY (1) UY26681A1 (de)
WO (1) WO2001081309A2 (de)
ZA (1) ZA200208134B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
JP2006515999A (ja) 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
JP2011516417A (ja) * 2008-03-27 2011-05-26 エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
BRPI0917948A2 (pt) 2008-08-12 2017-06-20 Zinfandel Pharrmaceuticals Inc métodos de identificar uma variante genética que está associada com o desenvolvimento de uma condição de interesse e um paciente em um ensaio clínico de um tratamento para doença de alzheimer, de determinar riscos incrementando de desenvolvimento de uma condição de interesse, doença de alzheimer em um paciente, de um prognóstico ou o risco de desenvolver doença de alzheimer em um paciente, de tratar um paciente para doença de alzheimer, uma condição de interesse e doença de alzheimer em um paciente, de estratificar um paciente em um subgrupo de um ensaio clínico de uma terapia para o tratamento de doença de alzheimer, uso de um agente ativo anti-doença de alzheimer e kits para determinar se um paciente encontra-se em risco incrementado de desenvolver doença de alzheimer e se um paciente é responsivo a tratamento para uma condição de interesse
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2878335B1 (de) 2013-11-10 2018-01-03 Brainsgate Ltd. Implantat und implantationssystem für nervenstimulator
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN109790149B (zh) * 2016-11-08 2022-05-17 豪夫迈·罗氏有限公司 苯氧基三唑类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
CN1178914C (zh) 2004-12-08
PE20011229A1 (es) 2001-12-08
UY26681A1 (es) 2001-10-25
BR0110233A (pt) 2003-01-21
CA2407345C (en) 2009-04-07
WO2001081309A2 (en) 2001-11-01
ATE313527T1 (de) 2006-01-15
EP1278730A2 (de) 2003-01-29
AR028357A1 (es) 2003-05-07
KR100527527B1 (ko) 2005-11-09
ES2254422T3 (es) 2006-06-16
JP2004509837A (ja) 2004-04-02
CN1443166A (zh) 2003-09-17
US6432985B2 (en) 2002-08-13
DK1278730T3 (da) 2006-05-01
ZA200208134B (en) 2004-01-22
EP1278730B1 (de) 2005-12-21
DE60116080T2 (de) 2006-08-24
AU785153B2 (en) 2006-10-05
WO2001081309A3 (en) 2002-01-17
AU6021301A (en) 2001-11-07
JP3831255B2 (ja) 2006-10-11
MXPA02010573A (es) 2003-03-10
KR20040007216A (ko) 2004-01-24
CA2407345A1 (en) 2001-11-01
US20010047014A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DE60116080D1 (de) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidin-3,4-diol
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ID28219A (id) Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol
IS6492A (is) Ný bíarýlkarboxamíð
DE60143749D1 (de) Segmentierter haftverschluss
DE60140969D1 (de) Bankomat
DE60128634D1 (de) Bankautomat
ID28483A (id) 2-(3,5-bis-trifluorometil-fenil)-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il)-isobutiramida
IT1320240B1 (it) Macchina curvatrice di profilati.
DE10193450D2 (de) Gehörschutzstöpsel
DE10085473T1 (de) Erodiermaschine
FI4460U1 (fi) Kalanteri
DE50007064D1 (de) Kalander
DE50102094D1 (de) Kalander
FI20000399A (fi) Kalanteri
FR2805883B1 (fr) Profile
FR2803483B1 (fr) Andaineuse frontale
DE50105888D1 (de) Kalander
DE50101830D1 (de) Kalander
FIU20000395U0 (fi) Kalanteri
SE0000045D0 (sv) JIT/JIM-Balk
ATA4452000A (de) Toupet
ES1047939Y (es) Caña de lavado total.
ES1047325Y (es) Rodillo perfeccionado.
ITVE20000004A1 (it) Sonda metrica.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition